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Abstract: 
Dexamethasone is a potent synthetic member of the glucocorticoid class of corticosteroid drugs that has been useful 
for the management of some pathological disorders because it affects a protean number of signaling pathways. It is 
used as adjunct therapy in the management of sepsis, arthritis, cardiac transplant, blood, hormone/immune system 
disorders, allergic reaction, skin, eye conditions, cancer and other pathologic disorders and as a mainstay of 
therapy in autoimmune hepatitis. With the advent of COVID-19, there have been investigations of its use as anti-
inflammatory agent in severely ill patients. This present review elucidates the various studies on the use of 
dexamethasone in the management of severe respiratory tract infections, with the ultimate aim of reducing 
mortality amongst severely ill patients, including COVID-19. 
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Abstrait: 
La dexaméthasone est un membre synthétique puissant de la classe des corticostéroïdes glucocorticoïdes qui a été 
utile pour la gestion de certains troubles pathologiques car elle affecte un nombre protéiforme de voies de 
signalisation. Il est utilisé comme traitement d'appoint dans la prise en charge de la septicémie, de l'arthrite, de la 
transplantation cardiaque, du sang, des troubles hormonaux/du système immunitaire, des réactions allergiques, 
des affections cutanées, oculaires, du cancer et d'autres troubles pathologiques et comme pilier du traitement de 
l'hépatite auto-immune. Avec l'avènement du COVID-19, des études ont été menées sur son utilisation comme 
agent anti-inflammatoire chez des patients gravement malades. Cette revue présente les différentes études sur 
l'utilisation de la dexaméthasone dans la prise en charge des infections sévères des voies respiratoires, dans le but 
ultime de réduire la mortalité chez les patients gravement malades, y compris le COVID-19. 
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 Dexamethasone is a potent synthetic 
member of the glucocorticoid class of cortico- 
steroid drugs (1). It was found useful for 
managing some pathological disorders because 
it affects a protean number of signaling path- 
ways. These effects may explain its therapeutic 
benefits when used in the management of 
sepsis, arthritis, cardiac transplant, blood, hor- 
mone/immune system disorders, allergic reac- 
tion, skin, eye conditions, cancer and other 
pathologic disorders (1). Dexamethasone is 
synthesized by dehydration of 16 β-methylpre- 
dnisolone acetate to give the 9,11 dehydro 
derivative, which is then reacted with a hydro- 
bromite source such as basic N, bromosuccini- 
mide to form 9α-bromo 11-β hydrin derivative, 
and the ring is then closed to form an epoxide. 
A ring opening reaction with hydrogen fluoride 
in tetrahydrofuran gives rise to dexamethasone 
(2). The adrenal glands also produce cortico- 
steroids naturally (3). These are steroid horm- 
ones which play important physiologic roles in 
the body such as glucose and protein meta- 
bolisms, and suppression of immune and infla- 
mmatory processes (3).   
 Most children will be infected by respi- 
ratory syncytial virus (RSV) before the age of 
two years (3). About 1% of them will need to 
be admitted to the hospital while respiratory 
failure will occur in 5-8% of cases, necessita- 
ting mechanical ventilation (3). Aspergillosis, 
asthma, and allergic broncho-pulmonary pneu- 
monia could cause reactive airway diseases, 
and corticosteroids could be useful in treatment 
of these conditions (4). Corticosteroids are also 
useful in the management of chronic obstru- 
ctive pulmonary diseases (COPD), sarcoidosis, 
collagen vascular diseases, eosinophilic pneu- 
monitis, idiopathic interstitial pneumonia and 
infectious disorders such as laryngo-tracheo-
bronchitis (4). In addition, patients with influ- 
enza virus (H1N1 strain) and severe coronavirus 
infections often need mechanical ventilation, 
and dexamethasone could be useful in their 
management (4).     
 The efficacy of corticosteroids in the 
management of patients with RSV-LRTI (lower 
respiratory tract infection) has been studied 
over the years with conflicting results. While 
some studies found beneficial effects, many 
well-designed randomized control trials did not 
show that corticosteroids are beneficial. How- 
ever, prednisolone shortened the length of hos- 
pital stay for patients on mechanical ventila- 
tion. A relevant research on influenza associa- 
ted pneumonia showed that low-moderate dose 
of corticosteroid reduced mortality in patients 
with oxygen index lower than 300 mmHg (5). 
The purpose of this review is to assess the use 
of dexamethasone in the treatment of respi- 
ratory tract infections (RTIs) with emphasis on 
its use for patients with COVID-19.   
Dexamethasone use in upper respiratory tract 
infections     
 The upper airway (nasopharynx, oro- 
pharynx, and laryngopharynx) conveys gases 
to and from the lungs, and filters, warms, and 
humidifies the air. The trachea and bronchi are 
lined by pseudo-stratified ciliated columnar epi- 
thelium which forms an active physical barrier 
against pathogens as an important part of the 
innate immunity (6). Goblet cells and mucus-
producing glands are also included in this area 
and are responsible for producing roughly 100 
ml of fluids/day in the adult, or more especially 
in disease state. All these provide protection 
against respiratory viral infections (6,7). How- 
ever, despite these protective mechanisms, 
infection occurs by virus binding to specific rec- 
eptors on epithelial cells of respiratory mucosa, 
thereby circumventing its removal by the mu- 
cociliary system or phagocytic cells (7).  
 Inspite of its clinical applications for up 
to 70 years, the role of corticosteroid as potent 
anti-inflammatory drug is still controversial in 
many pulmonary conditions (8). The role of 
dexamethasone in established viral infections 
such as severe acute respiratory syndrome- 
coronavirus-2 (SARS-CoV-2) infection (COVID-
19), has been variously reported (7). Following 
entry into the cytoplasm of the cell by passive 
diffusion, glucocorticoids interact with gluco- 
corticoid receptor (GR) to form a complex, 
which then moves into the nucleus where they 
either suppress or stimulate transcription, 
through a process called trans-repression or 
transactivation (9,10). Glucocorticoids inhibit 
transcription factors such as nuclear factor 
kappa B (NF-kβ) which are proteins that 
control the rate of transcription. Production of 
pro-inflammatory mediators by macrophages, 
eosinophils, lymphocytes, mast cells, and den- 
dritic cells are controlled by these transcription 
factors. Also important is the inhibitory effect 
on phospholipase A2 that produce various infla- 
mmatory mediators (10,11).   
 Glucocorticoids also inhibits the genes 
responsible for expression of cyclooxygenase-
2, inducible nitric oxide synthase, and proinfla- 
mmatory cytokines, tumor necrosis factor 
alpha and interleukins (9). In contrast, cortico- 
steroids initiate upregulation of lipocortin and 
of annexin A1, a protein that reduces prosta- 
glandin and leukotriene synthesis and that also 
inhibits cyclooxygenase-2 activity and reduces 




neutrophil migration to inflammatory sites. Be- 
cause corticosteroid action occurs intracellu- 
larly, the effects persist, even when detection 
in the plasma is absent (9,10,12). Cytokine 
storm has been implicated as the mainstay in 
the pathogenesis of COVID-19 (13). The use of 
glucocorticoids will therefore have a place in 
the management of the disease. Dexametha- 
sone is superior and preferred among other 
glucocorticoids due to its longer half-life and 
duration of action (24–36 hours), higher anti-
inflammatory activities (30 times higher than 
cortisol and six times higher than triamcino- 
lone), zero salt-retaining ability and most exce- 
llent penetration of lipid barriers for topical 
activity (10). 
Dexamethasone use in lower respiratory tract 
infection      
 Following lower respiratory tract infec- 
tion by any microorganism, cytokines and other 
inflammatory mediators are released by alveo- 
lar macrophages, which improves opsonization 
of the invading pathogens and usually lead to 
their successful removal (14). However, pro- 
found release of these cytokines and other 
inflammatory mediators can be detrimental to 
the host leading to significant damage to the 
lung parenchyma (14).   
 In a prospective study by Meduri et al., 
(15) involving 27 consecutive patients with 
acute respiratory distress syndrome (ARDS), 
patients who died from ARDS had raised levels 
of cytokines and inflammatory mediators on 
the first day of their admission and throughout 
their period of hospitalization. The persistent 
inflammatory response may contribute signifi- 
cantly to lung injury and subsequent respira- 
tory failure. The need to abate the excessive 
release of cytokine and inflammatory mediators 
in lung infections using dexamethasone has 
generated wide interest among researchers, al- 
though the routine uses of systemic cortico- 
steroid in the management of COVID-19 pneu- 
monia has not been recommended by the 
World Health Organization (16). Administration 
of dexamethasone leads to reduction in serum 
levels of cytokines and inflammatory cells, 
which subsequently reduce the cytokine storm 
to the barest minimum. Mortality amongst very 
ill patients with ARDS is thus greatly reduced. 
Dexamethasone as a glucocorticoid as well as 
an anti-inflammatory steroid, suppress expre- 
ssion of pro-inflammatory genes (17). 
 Corticosteroids also help reduce tissue 
injury and edema, and this is believed to 
alleviate patient’s distress from the accom- 
panying inflammatory process after tissue 
injury. The effects of dexamethasone use on 
outcome in patients with pneumonia however 
remains controversial. In a prospective study 
by Monton et al., (18) on 27 patients with 
severe pneumonia on mechanical ventilation, 
glucocorticoid (GC), dexamethasone, alleviated 
patient’s inflammatory response state. In this 
study, mortality rate in the patients who had 
treatment with GC was 36% (4/11), while for 
patients who did not receive GC, mortality rate 
was 67% (6/9). The survivors who received GC 
had reduced levels of serum TNF-α when 
compared to non survivors irrespective of their 
treatment with GC (18). It is good to note that 
despite the favorable outcome in reduction of 
risk of mortality reported in this study, other 
researchers have noticed a deleterious effect of 
use of corticosteroids in the treatment of lower 
respiratory tract infection. In the systematic 
review and meta-analysis involving 6548 pati- 
ents, Ni et al., (19) reported that corticosteroid 
use could increase the death rate in patients 
with influenza pneumonia.   
 As dexamethasone suppresses immune 
reactions by inhibiting inflammatory responses, 
thus inhibiting the migration of inflammatory 
mediators from the circulation to issues via 
inhibition of the synthesis of chemokines and 
cytokines (19), the fear of researchers is that 
modulation of immune responses caused by 
these corticosteroids can elongate the period of 
viraemia and hinder viral clearance, thereby 
increasing the risk of mortality (20). The report 
of prospective study by Li  et al., (5)  involving  
2141 hospitalized adolescent and adult patients 
with influenza A (H1N1) pdm09 viral pneu- 
monia from 407 hospitals in mainland China, 
shows  that  low mortality rate was noticed in  
patients with severe disease treated with low-
to-moderate dose corticosteroid, while patients  
with influenza pneumonia who had mild disease 
did not benefit from corticosteroid therapy. 
Meijvis et al., (22) also reported a significant 
reduction in the period of hospital admission in 
304 adult patients diagnosed with community-
acquired pneumonia and treated with intra- 
venous dexamethasone (5 mg once a day) or 
placebo for 4 days at two teaching hospitals in 
the Netherlands. However, these patients also 
had antibiotics included in their treatment and 
were non-immunocompromised (21).  
 In a recent large randomized control-
led study, 2104 patients with COVID-19 in the 
United Kingdom, randomly allocated to receive 
dexamethasone and other usual care (which 
included oxygen support, mechanical ventila 
tion/intensive care, treatment of intercurrent 
infections/diseases), were compared with 4321 
patients concurrently allocated to usual care 
only without administration of dexamethasone. 




Dexamethasone reduced deaths by one-third in 
patients receiving invasive mechanical venti- 
lation [29.0 vs 40.7%, age-adjusted rate ratio 
(RR); 0.65 (confidence interval 0.51 -0.82); 
p<0.001]; by one-fifth in patients receiving 
oxygen without invasive mechanical ventilation 
[1.5 vs 25.0%, RR 0.80 (95% CI 0.70 - 0.92); 
p=0.002); but did not reduce mortality in 
patients not receiving respiratory support at 
randomization (17.0 vs 13.2%, RR 1.22 (95% 
CI 0.93-1.61); p=0.14]. In patients hospita- 
lized with COVID-19, dexamethasone reduced 
28-day mortality among those receiving inva- 
sive mechanical ventilation or oxygen at rando- 
mization, but not among patients not receiving 
respiratory support (22). 
Discussion: 
 Dexamethasone is derived from cortisol 
(hydrocortisone) (2). It plays important physio- 
logic roles in the body such as glucose and 
protein metabolism, and suppression of imm- 
une and inflammatory processes (3). About 1% 
of children with RSV infection need to be 
admitted to hospital while respiratory failure 
progresses in 5-8% of them, necessitating me- 
chanical ventilation (3). Patients with severe 
RSV, influenza virus (H1N1), and coronavirus 
infections often need mechanical ventilation, 
and dexamethasone could be useful in their 
management (4). Relevant research has also 
shown that influenza associated pneumonia in 
patients with oxygen index lower than 300 
mmHg, low to moderate dose of corticosteroids 
significantly reduced mortality (5). Low oxygen 
index is a usual finding in COVID-19 patients 
with moderate to severe disease who require 
assisted ventilation. Although the role of corti- 
costeroids as potent anti-inflammatory drugs is 
still controversial in the management of many 
pulmonary conditions, dexamethasone has been 
found useful in reducing mortality in establi- 
shed viral infections such as COVID-19 (7,8). 
 Among the glucocorticoids, dexametha- 
sone is superior and preferred due to its longer 
half-life and duration of action (24–36 hours), 
its higher anti-inflammatory activities (30 times 
higher than cortisol and 6 times higher than 
triamcinolone), zero salt-retaining ability and 
most excellent penetration of lipid barriers for 
topical activity (10). In patients hospitalized 
with COVID-19, dexamethasone reduced 28-
day mortality among those receiving invasive 
mechanical ventilation or oxygen at randomi- 
zation, but not among patients not receiving 
respiratory support (22). It could therefore be 
safely concluded that patients with COVID-19 
experiencing cytokine storm, particularly those 
on mechanical/assisted ventilation will benefit 
from treatment with dexamethasone.  
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